Guofei Li

815 total citations
46 papers, 627 citations indexed

About

Guofei Li is a scholar working on Oncology, Pharmacology and Molecular Biology. According to data from OpenAlex, Guofei Li has authored 46 papers receiving a total of 627 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Pharmacology and 10 papers in Molecular Biology. Recurrent topics in Guofei Li's work include Drug Transport and Resistance Mechanisms (10 papers), Cancer therapeutics and mechanisms (6 papers) and Berberine and alkaloids research (6 papers). Guofei Li is often cited by papers focused on Drug Transport and Resistance Mechanisms (10 papers), Cancer therapeutics and mechanisms (6 papers) and Berberine and alkaloids research (6 papers). Guofei Li collaborates with scholars based in China and United States. Guofei Li's co-authors include Limei Zhao, Mingming Zhao, Feng Qiu, Cuifang Cai, Xing Tang, Xing Tang, Mei Liu, Yu Zhang, Futai Lu and Qiliang Deng and has published in prestigious journals such as Scientific Reports, International Journal of Pharmaceutics and Applied Surface Science.

In The Last Decade

Guofei Li

41 papers receiving 603 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guofei Li China 17 186 110 95 84 81 46 627
Mark Wirth United States 9 190 1.0× 75 0.7× 125 1.3× 124 1.5× 37 0.5× 9 663
Yasutaka Igari Japan 14 152 0.8× 100 0.9× 146 1.5× 143 1.7× 69 0.9× 19 603
Tae‐Sung Koo South Korea 17 235 1.3× 27 0.2× 99 1.0× 103 1.2× 40 0.5× 60 702
Senthil Venkatachalam India 13 130 0.7× 131 1.2× 127 1.3× 48 0.6× 34 0.4× 52 589
Deep Kwatra United States 16 238 1.3× 111 1.0× 80 0.8× 195 2.3× 70 0.9× 28 810
Feng Shao China 16 353 1.9× 144 1.3× 94 1.0× 102 1.2× 33 0.4× 51 756
Akira Saheki Japan 10 212 1.1× 60 0.5× 84 0.9× 197 2.3× 126 1.6× 13 672
Kazuki Matsui Japan 20 431 2.3× 75 0.7× 302 3.2× 74 0.9× 53 0.7× 76 1.1k

Countries citing papers authored by Guofei Li

Since Specialization
Citations

This map shows the geographic impact of Guofei Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guofei Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guofei Li more than expected).

Fields of papers citing papers by Guofei Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guofei Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guofei Li. The network helps show where Guofei Li may publish in the future.

Co-authorship network of co-authors of Guofei Li

This figure shows the co-authorship network connecting the top 25 collaborators of Guofei Li. A scholar is included among the top collaborators of Guofei Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guofei Li. Guofei Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chu, Chenxiao, Mingli Wei, Yuying Wang, et al.. (2025). Precision-targeted explosion of biomimetic nanoparticles for the effective treatment of uveal melanoma. International Journal of Pharmaceutics. 675. 125543–125543. 1 indexed citations
2.
Li, Guofei, et al.. (2025). Drug Interaction Potential of Berberine Hydrochloride When Co-Administered with Tofacitinib and Filgotinib in Rats. Drug Design Development and Therapy. Volume 19. 5043–5057. 1 indexed citations
3.
Dai, Jingjing, et al.. (2025). MoS2/MgAl-LDH Composites for the Photodegradation of Rhodamine B Dye. Inorganics. 13(3). 88–88.
4.
5.
Li, Guofei, et al.. (2025). recent advances in the pathogenesis of vitiligo and the application of novel drug delivery systems in its treatment. International Journal of Pharmaceutics X. 10. 100397–100397.
6.
Li, Guofei, et al.. (2024). The role of SIRT1-FXR signaling pathway in valproic acid induced liver injury: a quantitative targeted metabolomic evaluation in epileptic children. Frontiers in Pharmacology. 15. 1477619–1477619. 3 indexed citations
7.
Li, Guofei, Fang Hou, Ziqing Wang, et al.. (2023). Chlorin based metal-organic frameworks for highly selective and sensitive detection of phosphate. Microporous and Mesoporous Materials. 359. 112652–112652. 5 indexed citations
8.
Li, Guofei, et al.. (2023). Porphyrin based covalent organic polymer for the fluorescence sensing of water in organic solvents. Dyes and Pigments. 222. 111924–111924. 2 indexed citations
9.
Zhao, Limei, et al.. (2023). Research progress in nano-drug delivery systems based on the characteristics of the liver cancer microenvironment. Biomedicine & Pharmacotherapy. 170. 116059–116059. 24 indexed citations
10.
Zhao, Mingming, et al.. (2023). Development of a UPLC–MS/MS method for simultaneous therapeutic drug monitoring of anti-hepatocellular carcinoma drugs and analgesics in human plasma. Frontiers in Pharmacology. 14. 1136735–1136735. 2 indexed citations
11.
Yin, Xiaotong, et al.. (2022). Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy. CNS Neuroscience & Therapeutics. 28(5). 658–666. 13 indexed citations
12.
Li, Guofei, Mingming Zhao, & Limei Zhao. (2020). Lysine-mediated hydroxyethyl starch-10-hydroxy camptothecin micelles for the treatment of liver cancer. Drug Delivery. 27(1). 519–529. 22 indexed citations
13.
Li, Guofei, et al.. (2020). Circular RNA circ_DROSHA alleviates the neural damage in a cell model of temporal lobe epilepsy through regulating miR-106b-5p/MEF2C axis. Cellular Signalling. 80. 109901–109901. 23 indexed citations
14.
Zhao, Mingming, et al.. (2016). Simultaneous Determination of Valproic Acid and Its Major Metabolites by UHPLC-MS/MS in Chinese Patients: Application to Therapeutic Drug Monitoring. Journal of Chromatographic Science. 55(4). 436–444. 18 indexed citations
15.
Li, Guofei, Yan Li, Yilin Tang, et al.. (2014). Hydroxyethyl starch conjugates for improving the stability, pharmacokinetic behavior and antitumor activity of 10-hydroxy camptothecin. International Journal of Pharmaceutics. 471(1-2). 234–244. 40 indexed citations
16.
Teng, Fei, et al.. (2013). Parenteral formulation of larotaxel lipid microsphere tackling poor solubility and chemical instability. International Journal of Pharmaceutics. 460(1-2). 212–219. 9 indexed citations
17.
Li, Guofei, Cuifang Cai, Tianyang Ren, & Xing Tang. (2013). Development and application of a UPLC–MS/MS method for the pharmacokinetic study of 10-hydroxy camptothecin and hydroxyethyl starch conjugate in rats. Journal of Pharmaceutical and Biomedical Analysis. 88. 345–353. 9 indexed citations
18.
Liu, Zhenzhen, Yukun Feng, Guofei Li, et al.. (2013). Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel-loaded microsphere with larotaxel-solution. Cancer Chemotherapy and Pharmacology. 71(5). 1131–1139. 12 indexed citations
19.
Li, Guofei, Lili Zhang, Xiaoguang Tao, et al.. (2010). Preparation and evaluation of nicotinic acid sustained-release pellets combined with immediate release simvastatin. International Journal of Pharmaceutics. 400(1-2). 42–48. 13 indexed citations
20.
Li, Guofei, et al.. (2010). Isosorbide-5-mononitrate (5-ISMN) sustained-release pellets prepared by double layer coating for reducing 5-ISMN migration and sublimation. International Journal of Pharmaceutics. 400(1-2). 138–144. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark Wirth Breakdown of academic impact, for papers by Yasutaka Igari Breakdown of academic impact, for papers by Tae‐Sung Koo Breakdown of academic impact, for papers by Senthil Venkatachalam Breakdown of academic impact, for papers by Deep Kwatra Breakdown of academic impact, for papers by Feng Shao Breakdown of academic impact, for papers by Akira Saheki Breakdown of academic impact, for papers by Kazuki Matsui
Rankless by CCL
2026